Online inquiry

IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3049MR)

This product GTTS-WQ3049MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PTK7 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001270398.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5754
UniProt ID Q13308
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3049MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13147MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ14916MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ12432MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ7373MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ14298MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG-7221
GTTS-WQ1769MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ13379MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ5627MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP870
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW